Investing in pharmaceutical companies with diversified revenue bases and strong R&D pipelines could be a lucrative strategy.

In this week’s edition of InnovationRx, we look at the battle for Metsera, the departure of FDA’s top drug regulator, Kimberly-Clark’s $40 billion Kenvue deal, and more.

This article was reviewed by Darragh O’Carroll, MD. GLP-1 for Weight Loss: Everything You Need to Know Key takeaways: GLP-1s ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

Unregulated compounded GLP-1s are not the same as the legitimate medications that doctors prescribe for weight loss and chronic disease management.

The Trump administration plans to announce a deal with pharmaceutical companies to sell discounted weight-loss drugs through ...

There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle ...

Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.

U.S. pharmaceutical company Eli Lilly (LLY) says that the weight-loss pill it is developing should be a candidate for ...

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it before it's been fully tested.